Literature DB >> 10815904

Microregional heterogeneity of non-protein thiols in cervical carcinomas assessed by combined use of HPLC and fluorescence image analysis.

V Vukovic1, T Nicklee, D W Hedley.   

Abstract

Under low oxygen conditions, non-protein thiols (NPSHs, non-protein sulfhydryls) can effectively compete for DNA radicals sites and hence represent a potentially important cause of radiation resistance in the clinic. Intra- and intertumoral heterogeneity of glutathione (GSH) and cysteine were assessed in cryostat sections of multiple biopsies obtained from 10 cervical carcinomas by the combined use of a sensitive high-performance liquid chromatography (HPLC) method and a fluorescence image analysis technique to examine the spatial distribution of NPSHs in tumor tissue. Glutathione concentrations ranged from 1.98 to 4.42 mM; significant (> or =1 mM) concentrations of cysteine, a more effective radioprotector than GSH, were found in some tumors. By HPLC, the intratumoral heterogeneity of NPSHs was relatively small compared with the intertumoral heterogeneity. The histochemical stain 1-(4-chloromercuryphenoylazo)-2-napthol (mercury orange), which binds to GSH and cysteine, was used to determine the spatial distribution of NPSHs in tumor tissue. A comparison of NPSH levels in serial cryostat sections showed a close correlation between NPSH values determined by HPLC and mercury orange fluorescence quantification. Using fluorescence image analysis, an approximately 2-fold increase of NPSHs in tumor versus nonmalignant tissue was observed in the same section. Because some cervical carcinomas contain radiobiologically important levels of cysteine, agents that target the biochemical pathways maintaining tumor cysteine have therapeutic potential as adjuncts to radiotherapy in cervix cancer patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10815904

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  6 in total

1.  In vivo MR studies of glycine and glutathione metabolism in a rat mammary tumor.

Authors:  Peter E Thelwall; Nicholas E Simpson; Zahid N Rabbani; M Daniel Clark; Roxana Pourdeyhimi; Jeffrey M Macdonald; Stephen J Blackband; Michael P Gamcsik
Journal:  NMR Biomed       Date:  2011-07-12       Impact factor: 4.044

2.  A Novel ROS1-FBXL17 Fusion Co-Existing with CD74-ROS1 Fusion May Improve Sensitivity to Crizotinib and Prolong Progression-Free Survival of Patients with Lung Adenocarcinoma.

Authors:  Shaowei Lan; Hui Li; Ying Liu; Jinhua Xu; Zhicheng Huang; Shi Yan; Qiang Zhang; Ying Cheng
Journal:  Onco Targets Ther       Date:  2020-11-10       Impact factor: 4.147

Review 3.  Glutathione levels in human tumors.

Authors:  Michael P Gamcsik; Mohit S Kasibhatla; Stephanie D Teeter; O Michael Colvin
Journal:  Biomarkers       Date:  2012-08-20       Impact factor: 2.658

4.  Tumor Xenograft Response to Redox-Active Therapies Assessed by Magnetic Resonance Imaging Using a Thiol-Bearing DOTA Complex of Gadolinium.

Authors:  Gerald P Guntle; Bhumasamudram Jagadish; Eugene A Mash; Garth Powis; Robert T Dorr; Natarajan Raghunand
Journal:  Transl Oncol       Date:  2012-06-01       Impact factor: 4.243

5.  Human esophageal cancer is distinguished from adjacent esophageal tissue by tissue cysteine concentrations.

Authors:  S M Evans; R Lew; M L Kochman; E P Wileyto; E Baum; K M Safford; C J Koch
Journal:  Dig Dis Sci       Date:  2002-12       Impact factor: 3.199

6.  Hyperpolarized [1-13C]dehydroascorbate MR spectroscopy in a murine model of prostate cancer: comparison with 18F-FDG PET.

Authors:  Kayvan R Keshari; Victor Sai; Zhen J Wang; Henry F Vanbrocklin; John Kurhanewicz; David M Wilson
Journal:  J Nucl Med       Date:  2013-04-10       Impact factor: 10.057

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.